Leukocyte reduction of blood components: Public policy and new technology-Reference-Cited by-同舟云学术

Leukocyte reduction of blood components: Public policy and new technology

Published:2000-01 Issue:1 Volume:14 Page:34-52
ISSN:0887-7963
Container-title:Transfusion Medicine Reviews
language:en
Short-container-title:Transfusion Medicine Reviews

Author:

Dzik Sunny,Aubuchon James,Jeffries Leigh,Kleinman Steven,Manno Catherine,Murphy Michael F.,Popovsky Mark A.,Sayers Merlin,Silberstein Leslie E.,Slichter Sherril J.,Vamvakas Eleftherios C.

Publisher

Elsevier BV

Subject

Biochemistry (medical),Clinical Biochemistry,Hematology

Reference103 articles.

1. Leukocyte-reduced blood components: Current status;Klein,1998

2. The preparation of leukocyte-poor red cells for transfussion by a simple costeffective technique;Parravicini;Transfusion,1984

3. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions;Mangano;Am J Clin Pathol,1991

4. Prevalence of platelet transfusion reactions before and after implementation of leukocyte depleted platelet concentrates by filtration;Goodnough;Vox Sang,1993

5. The role of plasma from platelet concentrates in transfusion reactions;Heddle;N Engl J Med,1994

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Donors with repeated blood product discards for filtration problems, clots or hemolysis: Causes and follow‐up;Transfusion;2024-02-21

2. A retrospective observational study to estimate the risk of HLA alloimmunization with blood transfusion: Can the risk be reduced by leucodepletion?;Immunobiology;2023-09

3. Transfusion trigger after operations in high cardiac risk patients (TOP) trial protocol. Protocol for a multicenter randomized controlled transfusion strategy trial;Contemporary Clinical Trials;2023-03

4. Selective leukoreduction is all that we need in low- and middle-income countries;Global Journal of Transfusion Medicine;2023

5. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate;IRAN J BASIC MED SCI;2022